PET Imaging

Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enables visualization of metabolic processes in the body. The basics of PET imaging is that the technique detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (also called radiopharmaceuticals, radionuclides or radiotracer). The tracer is injected into a vein on a biologically active molecule, usually a sugar that is used for cellular energy. PET systems have sensitive detector panels to capture gamma ray emissions from inside the body and use software to plot to triangulate the source of the emissions, creating 3-D computed tomography images of the tracer concentrations within the body.

Lantheus Holdings, Inc. and RefleXion Medical, Inc., today announced a development and commercialization collaboration to evaluate the use of piflufolastat F 18, Lantheus’ prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging agent, to enable real-time therapeutic guidance of biology-guided radiotherapy (BgRT) in prostate cancer using the RefleXion X1 platform. 
News | PET Imaging
Lantheus and RefleXion Announce Collaboration with Potential to Improve Future Prostate Cancer Treatment

September 13, 2021 — Lantheus Holdings, Inc. and RefleXion Medical, Inc., today announced a development and ...

Time September 13, 2021
arrow
Plan to attend RSNA21 at McCormick Place Chicago, Nov. 28 – Dec. 2, 2021
News | RSNA
RSNA 2021 Showcases Latest Imaging Technologies, Solutions

September 13, 2021 — The Radiological Society of North America (RSNA) today announced highlights of the Technical ...

Time September 13, 2021
arrow
News | PET Imaging
Researchers Identify Mechanism That Can Help Guide Development of New STING-activating Drugs Using Imaging

September 8, 2021 — A new study from scientists at the UCLA Jonsson Comprehensive Cancer Center found that emerging ...

Time September 08, 2021
arrow
Gallium-68 from GalliaPharm is used for the preparation of diagnostic imaging drugs in Positron Emission Tomography (PET).
News | PET Imaging
Eckert & Ziegler Extends Gallium-68 Generator Portfolio in the United States

September 3, 2021 — Eckert & Ziegler Radiopharma GmbH has successfully submitted an amendment to their Drug Master File ...

Time September 03, 2021
arrow
Wisconsin-based company will help secure U.S. supply of Mo-99 used in 40,000 medical procedures daily, promote nuclear nonproliferation
News | Nuclear Imaging
NNSA Awards $37 Million to Promote U.S. Production of Critical Medical Isotope

August 27, 2021 — The U.S. Department of Energy’s National Nuclear Security Administration (NNSA) issued two cooperative ...

Time August 27, 2021
arrow
CDI Quality Institute, a non-profit affiliate of RAYUS Radiology, one of the nation's leading national subspecialty providers for advanced diagnostic and interventional radiology services, once again qualified as a Provider-led entity (PLE) for the Medicare Appropriate Use Criteria (AUC) Program with the Centers for Medicare & Medicaid Services (CMS)
News | Radiology Business
RAYUS Radiology Quality Institute Distinguished Nationally by Centers for Medicare & Medicaid

August 24, 2021 — CDI Quality Institute, a non-profit affiliate of RAYUS Radiology, one of the nation's leading national ...

Time August 23, 2021
arrow
#coronavirus #COVID19 #pandemic #RSNA21 will require all attendees and exhibitors to show proof of #vaccination and wear a #mask
News | RSNA
RSNA21 Will Require Proof of Vaccination, Masks

August 12, 2021 — RSNA 2021 will require proof of COVID-19 vaccination from all in-person attendees and exhibitors at ...

Time August 12, 2021
arrow
Cerium-134 can be targeted to provide an imaging analogue for two different therapy isotopes, actinium-225 and thorium-227. This helps scientists understand these therapy isotopes and develop new treatments. Image courtesy of Donald Montoya, Los Alamos National Laboratory
News | PET Imaging
New Imaging Isotope Meets Promising Therapy Isotopes

August 6, 2021 — A multidisciplinary team has demonstrated the production, purification, and potential application of ...

Time August 06, 2021
arrow
PET, PET imaging, PET-CT, FDG PET, PET cancer assessment, pet scanner, nuclear imaging, molecular imaging
News | PET-CT
The PET/CT Systems Market to Gel Well with Technological Upgrades

August 4, 2021 — PET/CT systems are expected to continue to incorporate the highest clinical performance of PET as well ...

Time August 04, 2021
arrow
Positrigo reports completion of the ExploreBPET clinical study, using the novel investigational medical device BPET for imaging of the human brain
News | PET Imaging
Successful Exploratory Clinical Study with Ultracompact Brain PET Sevice

August 3, 2021 — Positrigo, a company developing nuclear medical imaging devices that advance functional imaging ...

Time August 03, 2021
arrow
News | Molecular Imaging
Molecular Imaging Market to Reach $6.18 Billion

August 2, 2021 — The global molecular imaging market was evaluated at $4.199 billion for the year 2019 growing at a CAGR ...

Time August 02, 2021
arrow
Registration is now open for the Radiological Society of North America (RSNA) 107th Scientific Assembly and Annual Meeting, the world’s largest annual radiology forum, to be held at McCormick Place Chicago, Nov. 28 – Dec. 2, 2021
News | RSNA
Registration Now Open for RSNA21

July 21, 2021 — Registration is now open for the Radiological Society of North America (RSNA) 107th Scientific Assembly ...

Time July 21, 2021
arrow
News | PET Imaging
Swiss Nuclear Medical Imaging Company Gets Financial Boost

July 16, 2021 — Positrigo, a company developing nuclear medical imaging devices to advance functional imaging, today ...

Time July 16, 2021
arrow
Humana’s new draft Fusion policy outlines coverage determinations for myocardial assessment and the use of PET/CT and SPECT/CT for certain neurologic indications. ASNC has submitted additional feedback on the draft policy.
News | PET-CT
Humana Hears ASNC’s Concerns, Reverses Restrictive PET/CT Coverage Policy

July 13, 2021 — In a recent blog, the American Society of Nuclear Cardiology (ASNC) reported that Humana, one of the ...

Time July 13, 2021
arrow
A performance evaluation of the uEXPLORER total-body PET/CT scanner showed that it exhibits ultra-high sensitivity that supports excellent spatial resolution and image quality. Given the long axial field of view (AFOV) of the uEXPLORER, study authors have proposed new, extended measurements for phantoms to characterize total-body PET imaging more appropriately. This research was published in the June issue of The Journal of Nuclear Medicine.
News | PET Imaging
Total-body PET Imaging Exceeds Industry Standards

July 10, 2021 — A performance evaluation of the uEXPLORER total-body PET/CT scanner showed that it exhibits ultra-high ...

Time July 10, 2021
arrow
Aduhelm should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia
News | PET Imaging
FDA Approves Updated Aduhelm Prescribing Information

July 8, 2021 — Biogen and Eisai Co., Ltd. announced the U.S. Food and Drug Administration (FDA) has approved an updated ...

Time July 08, 2021
arrow
The RefleXion X1 is the world’s first biology-guided radiotherapy (BgRT) machine that’s expected to improve treatment and expand options for patients with metastatic disease, where few treatments are currently available.
News | Radiation Therapy
UPMC Hillman Cancer Center Among First in Country to Offer Radiotherapy That Lets Tumors Guide Treatment

June 29, 2021 — UPMC Hillman Cancer Center will be the first cancer center in the eastern United States, and one of just ...

Time June 29, 2021
arrow
The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate cancer, providing a more effective imaging approach to detect the spread of cancer to other parts of the body. Piflufolastat F-18 injection is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA and also the first commercially available PSMA PET imaging agent.
News | PET Imaging
FDA Approves First Commercially Available PSMA PET Imaging Agent for Prostate Cancer

June 28, 2021 — The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate ...

Time June 28, 2021
arrow
GE Healthcare also recently announced Xeleris V, a new virtualized, flexible AI-powered solution that provides clinicians secure access to data from anywhere – helping them make personalized care decisions and treatment recommendations that are at the heart of precision health.
News | Nuclear Imaging
GE Healthcare Advances Precision Health & Theranostics With New Products & Solutions

June 22, 2021 — At the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2021 summer conference, GE Healthcare ...

Time June 22, 2021
arrow
A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL in detecting and localizing recurrent prostate cancer.
News | Prostate Cancer
PSMA-Targeted Radiotracer Pinpoints Metastatic Prostate Cancer Across Anatomic Regions

June 21, 2021 — A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen ...

Time June 21, 2021
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now